Table 1 Clinical characteristics of COAD samples from the TCGA database.
From: The anoikis-related gene signature predicts survival accurately in colon adenocarcinoma
Basic characteristics | Variables | Overall (N = 426) |
|---|---|---|
Age (years) | Median (1st Qu, 3rd Qu) | 68.00 (58.00, 77.00) |
Sex | Male | 229 (53.8%) |
Female | 197 (46.2%) | |
History of colon polyps | Yes | 127 (29.8%) |
No | 234 (54.9%) | |
Unknown | 65 (15.3%) | |
History of neoadjuvant treatment | Yes | 3 (0.7%) |
No | 423 (99.7%) | |
Histological type | Colon adenocarcinoma | 363 (85.2%) |
Colon mucinous adenocarcinoma | 59 (13.9%) | |
Unknown | 4 (0.9%) | |
TNM stage | Stage I | 75 (17.6%) |
Stage II | 167 (39.2%) | |
Stage III | 124 (29.1%) | |
Stage IV | 60 (14.1%) | |
T stage | T1 | 11 (2.6%) |
T2 | 74 (17.4%) | |
T3 | 292 (68.5%) | |
T4 | 49 (11.5%) | |
N stage | N0 | 251 (58.9%) |
N1 | 101 (23.7%) | |
N2 | 74 (17.4%) | |
M stage | M0 | 365 (85.7%) |
M1 | 61 (14.3%) | |
Longest dimension(cm) |  ≤ 1 cm | 125 (29.3%) |
 > 1 cm | 124 (29.1%) | |
Unknown | 177 (41.6%) | |
Residual tumor | R0 | 310 (72.8%) |
R1 | 4 (0.9%) | |
R2 | 21 (4.9%) | |
Rx | 91 (21.4%) | |
Survival status | Alive | 334 (78.4%) |
Dead | 92 (21.6%) | |
OS.time (mouths) | Median (1st Qu, 3rd Qu) | 13.23 (23.07,36.50) |
Progression-free-survival status | No progressive disease | 311 (73.0%) |
Progressive disease | 115 (27.0%) | |
PFS.time (mouths) | Median (1st Qu, 3rd Qu) | 20.28 (12.22,33.52) |
